Alzheimer's disease (AD) is the most widespread neurodegenerative disorder. Despite the severity of the disease,early diagnosis of AD is still challenging due to the low accuracy or high cost of neuropsychological tests andneuroimaging. Development of an accurate and cost-effective technology for non-invasive screening andmonitoring of AD before irreversible brain damage or mental decline is critical. WellSIM proposes to develop andvalidate a highly sensitive immunofluorescence assay, termed EXODOTS, for detection and quantification of ADcore biomarkers from circulating extracellular vesicles (EV) with high accuracy, high speed, and low cost. Thisblood-based assay will facilitate minimally invasive assessment of AD patients in primary care settings andcontinuous monitoring of disease progression.
Public Health Relevance Statement: PROJECT NARRATIVE
Although cerebrospinal fluid (CSF) is considered the optimal source of Alzheimer's disease (AD) biomarkers,
collection of CSF is a highly invasive outpatient procedure with potential complications, limiting its wide
applications in AD diagnostics. On the other hand, measuring the AD-related biomarkers from blood has poor
accuracy due to their much lower concentration and the complexity of blood components. The proposed
technology will provide a rapid and sensitive while low-cost approach for blood-based AD biomarker analysis,
which will facilitate non-invasive diagnostic evaluation of AD at its early stage.
Project Terms: | <Ï Proteins>
| |
